Expression of SIRT1 in choroidal neovascular membranes

Retina

Volumn 33, Issue 4, 2013, Pages 862-866

  Maloney, Shawn C ^a   Antecka, Emilia ^a   Granner, Tamara ^a   Fernandes, Bruno ^a   Lim, Li Anne ^a   Orellana, Maria E ^a   Burnier, Miguel N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR BB; SIRTUIN 1; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; PATHOGENESIS; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; CYTOKINES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; RETINAL PIGMENT EPITHELIUM; SIRTUIN 1; TISSUE DONORS; VITAMIN B COMPLEX; WET MACULAR DEGENERATION;

EID: 84875939523     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31826af556     Document Type: Article

References (29)

1. Friedman DS, O'Colmain BJ, Munoz B, et al.Prevalence of age-related macular degeneration in the United States.Arch Ophthalmol 2004;122:564-572
2. Mizukami Y, Jo WS, Duerr EM, et al.Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.Nat Med 2005;11:992-997
3. Dorrell MI, Aguilar E, Scheppke L, et al.Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.Proc Natl Acad Sci U S A 2007;104:967-972
4. Korte GE, Gerszberg T, Pua F, Henkind P.Choriocapillaris atrophy after experimental destruction of the retinal pigment epithelium in the rat.A study in thin sections and vascular casts.Acta Anat (Basel) 1986;127:171-175
5. Sakamoto T, Sakamoto H, Murphy TL, et al.Vessel formation by choroidal endothelial cells in vitro is modulated by retinal pigment epithelial cells.Arch Ophthalmol 1995;113: 512-520
6. Blaauwgeers HG, Holtkamp GM, Rutten H, et al.Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris.Evidence for a trophic paracrine relation.Am J Pathol 1999; 155:421-428
7. Miller H, Miller B, Ryan SJ.The role of retinal pigment epithelium in the involution of subretinal neovascularization.Invest Ophthalmol Vis Sci 1986;27:1644-1652
8. Imai S, Armstrong CM, Kaeberlein M, Guarente L.Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.Nature 2000;403:795-800
9. Howitz KT, Bitterman KJ, Cohen HY, et al.Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.Nature 2003;425:191-196
10. Lin SJ, Defossez PA, Guarente L.Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae.Science 2000;289:2126-2128
11. Bordone L, Motta MC, Picard F, et al.Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells.PLoS Biol 2006;4:e31
12. Banks AS, Kon N, Knight C, et al.SirT1 gain of function increases energy efficiency and prevents diabetes in mice.Cell Metab 2008;8:333-341
13. Milne JC, Lambert PD, Schenk S, et al.Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.Nature 2007;450:712-716
14. Potente M, Ghaeni L, Baldessari D, et al.SIRT1 controls endothelial angiogenic functions during vascular growth.Genes Dev 2007;21:2644-2658
15. Lee HI, Jang SY, Kang HT, Hwang ES.p53-, SIRT1-, and PARP-1-independent downregulation of p21WAF1 expression in nicotinamide-Treated cells.Biochem Biophys Res Commun 2008;368:298-304
16. Idelson M, Alper R, Obolensky A, et al.Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells.Cell Stem Cell 2009;5:396-408
17. Potente M, Dimmeler S.Emerging roles of SIRT1 in vascular endothelial homeostasis.Cell Cycle 2008;7:2117-2122
18. Brown DM, Kaiser PK, Michels M, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med 2006;355:1432-1444
19. Rosenfeld PJ, Brown DM, Heier JS, et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med 2006;355:1419-1431
20. Martin DF, Maguire MG, Ying GS, et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med 2011;364:1897-1908
21. Vascular endothelial growth factor (VEGF) trap-eye: Investigation of efficacy and safety in wet age-related macular degeneration (VIEW1).2011
22. Vascular endothelial growth factor (VEGF) trap-eye: Investigation of efficacy and safety in wet age-related macular degeneration (VIEW 2).2011
23. Brown DM, Michels M, Kaiser PK, et al.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.Ophthalmology 2009;116:57-65.e5
24. Schaal S, Kaplan HJ, Tezel TH.Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-2205
25. Cho M, Barbazetto IA, Freund KB.Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.Am J Ophthalmol 2009;148:70-78.e1
26. Rouvas AA, Papakostas TD, Vavvas D, et al.Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: A prospective study.Retina 2009;29: 536-544
27. Regillo CD, Brown DM, Abraham P, et al.Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1.Am J Ophthalmol 2008;145:239-248
28. Fung AE, Lalwani GA, Rosenfeld PJ, et al.An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.Am J Ophthalmol 2007;143:566-583
29. Holz FG, Amoaku W, Donate J, et al.Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: The SUSTAIN study.Ophthalmology 2011;118:663-671